中国药业2024，Vol.33Issue(12)：110-115,6.DOI:10.3969/j.issn.1006-4931.2024.12.025
胸腺五肽治疗带状疱疹有效性和安全性Meta分析
Effectiveness and Safety of Thymopentin in the Treatment of Herpes Zoster:A Meta-Analysis
摘要
Abstract
Objective To provide evidence for the clinical use of thymopentin in the treatment of herpes zoster.Methods Randomized controlled trials of thymopentin in the treatment of herpes zoster in the CNKI,CBM,VIP,WanFang,PubMed,Embase and The Cochrane Library from the inception of each database to November 2023 were collected.The RoB 2.0 tool of the Cochrane manual was used to evaluate the quality of studies,the RevMan 5.4 software was used for Meta-analysis,and the GRADE tool was used for evidence quality assessment of outcome indicators.Results A total of seven studies were included,all in Chinese,involving 471 patients.The Meta-analysis showed that the pain relief time[MD=-1.62,95%CI(-2.29,-0.96),P<0.001],pain disappearance time[MD=-3.07,95%CI(-3.74,-2.39),P<0.001],effective rate[RR=1.13,95%CI(1.04,1.22),P=0.002],and incidence of adverse reactions[RR=0.41,95%CI(0.19,0.91),P=0.03]in the test group were significantly better than those in the control group,but the scabbing time in the test group was similar to that in the control group[MD=-1.12,95%CI(-2.44,0.20),P=0.10].The quality of evidence was low or very low.Conclusion Thymopentin therapy is more effective and safer than simple antiviral therapy for herpes zoster,but the evidence for current conclusion is relatively low,lacking robust support for clinical practice and requiring more high-quality researches to confirm.关键词
胸腺五肽/带状疱疹/有效性/安全性/Meta分析/证据质量Key words
thymopentin/herpes zoster/effectiveness/safety/Meta-analysis/evidence quality分类
医药卫生引用本文复制引用
王雨,刘宇,杨佳丹,王红梅,宋捷..胸腺五肽治疗带状疱疹有效性和安全性Meta分析[J].中国药业,2024,33(12):110-115,6.基金项目
重庆医科大学未来医学青年创新团队发展支持计划[W0014]. （）
